US2004029872A1PendingUtilityA1

Inhibition of psychostimulant-induced and nicotine-induced craving

50
Assignee: GEN HOSPITAL CORPPriority: Sep 24, 1997Filed: Feb 10, 2003Published: Feb 12, 2004
Est. expirySep 24, 2017(expired)· nominal 20-yr term from priority
Inventors:Hans C. BreiterBruce R. RosenJohn J. A. MarotaJoseph B. MandevilleBarry E. Kosofsky
A61K 31/5415A61K 31/4741A61K 31/4515A61K 31/472A61K 31/4743A61K 31/00A61K 31/496A61K 31/55A61K 31/4745A61K 31/48A61K 31/438A61K 31/473A61K 31/4725
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides methods for inhibiting psychostimulant-induced or nicotine-induced craving of additional psychostimulants (e.g., cocaine or amphetamine) or nicotine. In these methods, D1-like antagonists or D1-like agonists are administered to a patient dependent on psychostimulant drugs or nicotine and therefore susceptible to, or suffering from, such a craving. Also disclosed is an animal model system useful for measuring the ability of test compounds to inhibit psychostimulant-induced or nicotine-induced cravings in humans.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for inhibiting a psychostimulant-induced craving in a human, the method comprising: 
 identifying the human as being psychostimulant-dependent and    administering to the human a D1-like antagonist or D1-like agonist in an amount effective to inhibit craving of a psychostimulant.    
     
     
         2 . The method of  claim 1 , wherein the psychostimulant is cocaine.  
     
     
         3 . The method of  claim 1 , wherein the psychostimulant is amphetamine.  
     
     
         4 . The method of  claim 1 , wherein the human is a compulsive psychostimulant user.  
     
     
         5 . The method of  claim 1 , wherein a D1-like antagonist is administered to the human.  
     
     
         6 . The method of  claim 5 , wherein the D1-like antagonist is selected from the group consisting of SCH 39166; SCH 23388; SCH 23390; A-69024; bulbocapnine; butaclamol HCl, (+)-; fluphenzanine HCl; flupenthixol 2 HCl, cis-(Z)-, fluspirilene; haloperidol; SCH-12679; SKF-83566; thioridazine HCl; thiothixine HCl; trifluoperazine 2HCl; and trifluorperidol HCl.  
     
     
         7 . The method of  claim 5 , wherein the D1-like antagonist is administered at a dosage of 0.0001 to 100 mg/kg of the body weight of the human.  
     
     
         8 . The method of  claim 1 , wherein a D1-like agonist is administered to the human.  
     
     
         9 . The method of  claim 8 , wherein the D1-like agonist is selected from the group consisting of A-86929; SKF 81297; SKF 38393; A-69024, N-allylnorapomorphine HBr, R(−)-; apomorphine HCl, R(−)-; 6-bromo-APB HBr, r(+)-; 6-Chloro-APB HBr, (±)-(SKF-82958); Pergolide methanesulfonate, and SKF 77434.  
     
     
         10 . The method of  claim 8 , wherein the D1-like agonist is administered at a dosage of 0.0001 to 100 mg/kg of the body weight of the human.  
     
     
         11 . The method of  claim 1 , wherein the D1-like antagonist or D1-like agonist is administered intravenously.  
     
     
         12 . The method of  claim 1 , wherein the D1-like antagonist or D1-like agonist is administered within 0 to 168 hours of consumption of a psychostimulant by the human.  
     
     
         13 . A method for inhibiting nicotine-induced craving in a human, the method comprising: 
 identifying the human as being nicotine-dependent and    administering to the human a D1-like antagonist or D1-like agonist in an amount effective to inhibit craving of nicotine.    
     
     
         14 . The method of  claim 13 , wherein the human is a compulsive nicotine user.  
     
     
         15 . The method of  claim 13 , wherein a D1-like antagonist is administered to the human.  
     
     
         16 . The method of  claim 15 , wherein the D1-like antagonist is selected from the group consisting of SCH 39166; SCH 23388; SCH 23390; A-69024; bulbocapnine; butaclamol HCl, (+)-; fluphenzanine HCl; flupenthixol 2 HCl, cis-(Z)-, fluspirilene; haloperidol; SCH-12679; SKF-83566; thioridazine HCl; thiothixine HCl; trifluoperazine 2HCl; and trifluorperidol HCl.  
     
     
         17 . The method of  claim 15 , wherein the D1-like antagonist is administered at a dosage of 0.0001 mg/kg to 100 mg/kg of the body weight of the human.  
     
     
         18 . The method of  claim 13 , wherein a D1-like agonist is administered to the human.  
     
     
         19 . The method of  claim 18 , wherein the D1-like agonist is selected from the group consisting of A-86929; SKF 81297; SKF 38393; A-69024, N-allylnorapomorphine HBr, R(−)-; apomorphine HCl, R(−)-; 6-bromo-APB HBr, r(+)-; 6-Chloro-APB HBr,(±)-(SKF-82958); Pergolide methanesulfonate, and SKF 77434.  
     
     
         20 . The method of  claim 18 , wherein the D1-like agonist is administered at a dosage of 0.0001 mg/kg to 100 mg/kg of the body weight of the human.  
     
     
         21 . The method of  claim 13 , wherein the D1-like antagonist or D1-like agonist is administered intravenously.  
     
     
         22 . The method of  claim 13 , wherein the D1-like antagonist or D1-like agonist is administered within 0 to 168 hours of consumption of nicotine by the human.

Join the waitlist — get patent alerts

Track US2004029872A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.